Sign up now for ease of access to The Medical Independent, Ireland’s most frequently published medical newspaper, delivering award-winning news and investigative reporting.

  • receive the eCopy two days prior to the printed edition.
  • can partake in our online MCQs.
  • can enter our online sports quiz.


Medicalindependent.ie is Ireland's only investigative medical news website for doctors, healthcare professionals and anyone with an interest in health issues.

Established in 2010, along with its sister publication The Medical Independent, our stated aim is to investigate and analyse the major issues affecting healthcare and the medical profession in Ireland. The Medical Independent has won a number of awards for its investigative journalism, and its stories are frequently picked up by national digital, broadcast and print media. The Medical Independent is published by GreenCross Publishing.

Address: Top Floor, 111 Rathmines Road Lr, Dublin 6

Tel: 353 (01) 441 0024

GreenCross Publishing is owned by Graham Cooke.

New initiatives needed to promote biosimilar prescribing — Prof Barry

By Mindo - 24th Apr 2019 | 12 views

Online reimbursement application systems and incentivised prescribing need to be considered to promote prescribing of biosimilars, Clinical Director of the National Centre for Pharmacoeconomics (NCPE) Prof Michael Barry has told the Medical Independent (MI).

Speaking to MI following his address at the recent Access to Medicines Ireland annual conference in the RCSI, Prof Barry also called on the HSE and the Department of Health to show leadership in promoting the use of biosimilars.

“Well, I think we are all employed by the HSE, we are HSE employees, so I think the HSE will need to push it,” Prof Barry told MI when asked about leadership in promoting biosimilars. “I think the Department of Health will need to do so as well.”

Prof Michael Barry

Prof Barry said the NCPE would soon be naming “biosimilars of first choice” for a number of drugs, which would “make things easier” for prescribers.

 “We need to make sure people are aware of that, so that they know which one is offering the best price and that there are significant price differences. And the challenge is then implementing it,” Prof Barry said.

A range of policies could be examined, added Prof Barry, who referred to incentivising biosimilar-prescribing “maybe by investing into the therapeutic area”.

“Or you could look at systems like reimbursement application systems, where if people were prescribing a particular drug, if they were prescribing anything other then the preferred [biosimilar] one, they would have to come online, apply for it and justify it, and we could say ‘yes’ or ‘no’ to reimbursement. So these are the sort of things that are being discussed at the moment.”

Meanwhile, Prof Barry said reimbursing drugs that are not cost-effective has an adverse impact on other areas of the health service. He also referred to lobbying of politicians by the pharmaceutical industry as “an issue”.

Leave a Reply

Latest
Latest Issue
medical news
The Medical Independent 19th May 2022

You need to be logged in to access this content. Please login or sign up using the links below.

Most Read